BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

SALVAT 

C\ Gall, 30-36
Esplugues de Llobregat
Barcelona    08950  Spain
Phone: 349-3394-6400 Fax: 349-3473-2292


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical






 Company News
SALVAT Announces Positive Top-Line Results From Two Phase 3 Studies Of Its Novel Otic Antibiotic/Steroid Combination Solution In The Treatment Of AOMT With Tympanostomy Tubes 9/29/2014 9:38:10 AM
SALVAT Completes Enrollment of Phase III Study for a New Combination in Acute Otitis Media in Pediatric Patients With Tympanostomy Tubes (AOMT) 5/28/2013 9:40:15 AM
SALVAT and Kwang Dong Pharmaceutical Announced Positive Results of Phase IIb for Tarafenacin for Overactive Bladder Treatment 4/10/2013 6:42:51 AM
Laboratorios SALVAT, S.A. and WraSer Pharmaceuticals, LLC Announce Exclusive License Agreement for the Commercialization of CETRAXAL(R) (ciprofloxacin otic solution) 0.2% 7/8/2009 11:14:27 AM
SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R) 11/6/2008 10:01:10 AM
SALVAT Has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder 10/10/2007 11:08:29 AM
SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 10/10/2007 7:34:36 AM
Chiesi Farmaceutici SpA And SALVAT Sign A Worldwide Development And Licensing Agreement For M3 Muscarinic Receptor Antagonists 1/9/2006 12:30:24 PM
SALVAT Seeks FDA Approval For Its CETRAXAL Otic (Ciprofloxacin Otic) 0.2% Solution, For The Treatment Of External Otitis10/19/2005 5:13:04 PM
SALVAT Seeks FDA Approval For its CETRAXAL Otic (ciprofloxacin otic) 0.2% Solution, For The Treatment Of External Otitis10/19/2005 5:10:58 PM
12